FURIN and breast carcinoma: Of note, ERBB2 exon 20 insertions were detected in 93 (0.6%) patients, accounting for 29.0% of all detected ERBB2 SNV/indels, including 86 with lung cancer, two with pancreas cancer, one with breast cancer, etc. The top mutated ERBB2 SNVs/indels were ERBB2 p.Y772_A775dup (82/321, 25.5%), a type of in-frame insertion within the exon 20 of the tyrosine kinase domain, and p.S310F/Y (64/321, 19.9%) in furin-like cysteine-rich region, followed by p.R678Q (43/321, 13.4%) in the transmembrane domain, and p.V842I (26/321, 8.1%) in the tyrosine kinase domain, etc. (Figure 1C; Table 2).